Exploring the impact of dexamethasone on gene regulation in myeloma cells
Victor Bessonneau-Gaborit,Jonathan Cruard,Catherine Guerin-Charbonnel,Jennifer Derrien,Jean-Baptiste Alberge,Elise Douillard,Magali Devic,Sophie Deshayes,Loïc Campion,Frank Westermann,Phillipe Moreau,Carl Herrmann,Jérémie Bourdon,Florence Magrangeas,Stéphane Minvielle,Bessonneau-Gaborit,V.,Cruard,J.,Guerin-Charbonnel,C.,Derrien,J.,Alberge,J.-B.,Douillard,E.,Devic,M.,Deshayes,S.,Campion,L.,Westermann,F.,Moreau,P.,Herrmann,C.,Bourdon,J.,Magrangeas,F.,Minvielle,S.
DOI: https://doi.org/10.26508/lsa.202302195
IF: 5.781
2023-08-01
Life Science Alliance
Abstract:Among glucocorticoids (GCs), dexamethasone (Dex) is widely used in treatment of multiple myelomas. However, despite a definite benefit, all patients relapse. Moreover, the molecular basis of glucocorticoid efficacy remains elusive. To determine genomic response to Dex in myeloma cells, we generated bulk and single-cell multi-omics data and high-resolution contact maps of active enhancers and target genes. We show that a minority of glucocorticoid receptor-binding sites are associated with enhancer activity gains, increased interaction loops, and transcriptional activity. We identified and characterized a predominant enhancer enriched in cohesin (RAD21) and more accessible upon Dex exposure. Analysis of four gene-specific networks revealed the importance of the CTCF–cohesin couple and the synchronization of regulatory sequence openings for efficient transcription in response to Dex. Notably, these epigenomic changes are associated with cell-to-cell transcriptional heterogeneity, in particular, lineage-specific genes. As consequences, BCL2L11 -encoding BIM critical for Dex-induced apoptosis and CXCR4 protective from chemotherapy-induced apoptosis are rather up-regulated in different cells. In summary, our work provides new insights into the molecular mechanisms involved in Dex escape.
biology